Here's how Google is trying -- and so far failing -- to transform medicine

Google employees, squeezed onto metal risers and standing in the back of a meeting room, erupted in cheers as newly arrived executive Andrew Conrad announced they would try to turn science fiction into reality: The tech giant had formed a biotech venture to create a futuristic device like Star Trek's iconic "Tricorder" diagnostic wizard -- and use it to cure cancer. Conrad, recalled an employee who was present, displayed images on the room's big screens showing nanoparticles tracking down cancer cells in the bloodstream and flashing signals to a Fitbit-style wristband. He promised a working prototype of the cancer early-detection device within six months. That was three years ago. Recently departed employees said the prototype didn't work as hoped, and the Tricorder project is floundering. Tricorder is not the only misfire for Google's ambitious and extravagantly funded biotech venture, now named Verily Life Sciences. It has announced three signature projects meant to transform medicine, and a STAT examination found that all of them are plagued by serious, if not fatal, scientific shortcomings, even as Verily has vigorously promoted their promise.